Malaria Treatment Guidelines

Introduction to Malaria Treatment

The World Health Organization recommends artemisinin-based combination therapy (ACT) as the best treatment for malaria, with specific regimens determined by the Plasmodium species, disease severity, and patient factors 1, 2

For uncomplicated P. falciparum malaria, the first-line treatment is oral artemisinin-based combination therapy (ACT), with options including artemether-lumefantrine and dihydroartemisinin-piperaquine 1, 3, 2
The American Society of Tropical Medicine and Hygiene recommends that artemether-lumefantrine be taken with fatty food to enhance absorption, with a dosage of 4 tablets at 0 hours, 4 tablets at 8 hours on day 1, then 4 tablets twice daily on days 2 and 3 2
The Centers for Disease Control and Prevention recommends dihydroartemisinin-piperaquine be taken while fasting, with a dosage of 3 tablets daily for 3 days (36-75 kg) or 4 tablets daily for 3 days (>75 kg) 2

For severe malaria, the first-line treatment is intravenous artesunate, with monitoring of parasitemia every 12 hours until <1%, then every 24 hours until negative 3
The Infectious Diseases Society of America recommends transitioning to oral therapy when parasite level is <1% and patient can tolerate oral medication 3
Post-treatment monitoring should include checking for delayed hemolysis on days 7, 14, 21, and 28 3

The World Health Organization recommends initial treatment with ACT or chloroquine (in chloroquine-sensitive regions), followed by radical cure with primaquine or tafenoquine to eliminate liver hypnozoites and prevent relapse 4, 2
The Centers for Disease Control and Prevention recommends testing for G6PD deficiency before administering primaquine or tafenoquine 2

For pregnant women, the Centers for Disease Control and Prevention recommends quinine plus clindamycin in the first trimester when other options are unavailable, and artemether-lumefantrine in the second and third trimesters 5
The American College of Obstetricians and Gynecologists recommends that artemether-lumefantrine be used as a treatment option throughout pregnancy when other treatments are unavailable 5

Failure to ensure adequate fat intake with artemether-lumefantrine administration can result in subtherapeutic drug levels and treatment failure, as noted by the World Health Organization 2
Delayed diagnosis of P. falciparum malaria is associated with increased mortality, according to the Infectious Diseases Society of America 3
Both artemether-lumefantrine and dihydroartemisinin-piperaquine can cause QTc interval prolongation, and should be avoided in patients at risk for QTc prolongation or taking medications that prolong QTc, as recommended by the American Heart Association 2